- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- LEGN
- Stock Information
- Founded
- AES 1981
- LEGN 2014
- Country
- AES United States
- LEGN United States
- Employees
- AES N/A
- LEGN N/A
- Industry
- AES Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- LEGN Health Care
- Exchange
- AES Nasdaq
- LEGN Nasdaq
- Market Cap
- AES 10.4B
- LEGN 6.3B
- IPO Year
- AES 1991
- LEGN 2020
- Fundamental
- Price
- AES $14.43
- LEGN $33.13
- Analyst Decision
- AES Hold
- LEGN Buy
- Analyst Count
- AES 9
- LEGN 11
- Target Price
- AES $13.63
- LEGN $71.90
- AVG Volume (30 Days)
- AES 13.1M
- LEGN 1.2M
- Earning Date
- AES 11-04-2025
- LEGN 11-11-2025
- Dividend Yield
- AES 4.87%
- LEGN N/A
- EPS Growth
- AES 8.40
- LEGN N/A
- EPS
- AES 1.28
- LEGN N/A
- Revenue
- AES $12,032,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- AES $2.67
- LEGN $70.27
- Revenue Next Year
- AES $4.34
- LEGN $50.28
- P/E Ratio
- AES $11.27
- LEGN N/A
- Revenue Growth
- AES N/A
- LEGN 74.75
- 52 Week Low
- AES $9.46
- LEGN $27.34
- 52 Week High
- AES $18.31
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- AES 57.98
- LEGN 48.04
- Support Level
- AES $14.05
- LEGN $31.18
- Resistance Level
- AES $14.89
- LEGN $33.21
- Average True Range (ATR)
- AES 0.48
- LEGN 1.19
- MACD
- AES 0.06
- LEGN 0.12
- Stochastic Oscillator
- AES 57.37
- LEGN 83.36
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.